ଡୋଷ୍ଟାରଲିମାବ

ଡୋଷ୍ଟାରଲିମାବ
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	PDCD1
Clinical data
Trade names	Jemperli
Synonyms	TSR-042, WBP-285, dostarlimab-gxly
data	EU EMA: yes; US DailyMed: Dostarlimab;
Pregnancy; category	AU: D ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6420H9832N1690O2014S44
Molar mass	୧,୪୪,୩୨୫.୭୩ g·mol−1

ଡୋଷ୍ଟାରଲିମାବ, ବେପାର ନାମ ଜେମପର୍ଲି, ହେଉଛି ଏକ ଔଷଧ ଯାହାକି ଗର୍ଭାଶୟ ଅନ୍ତସ୍ଟର କର୍କଟ ବା ଏଣ୍ଡୋମେଟ୍ରିଆଲ୍ କର୍କଟ ପରି କେତେକ କଠିନ ଅର୍ବୁଦମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୫] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବାରମ୍ବାର ବେମେଳ ମରାମତି ଅଭାବ (dMMR) ବାରମ୍ବାର କିମ୍ବା ଉନ୍ନତ କର୍କଟ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୫] ୪୪% ମାମଲାରେ ଉପକାର ଦେଖିବାକୁ ମିଳିଥିଲା । ^[୬] ଏହା ଧୀରେ ଧୀରେ ଶିରାରେ ଇଞ୍ଜେକ୍ସନ ଦେଇ ଦିଆଯାଏ । ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କା, ବାନ୍ତି,ତରଳ ଝାଡ଼ା ଏବଂ ରକ୍ତହୀନତା ହୋଇପାରେ ।^[୫] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, କୁଞ୍ଚନ, ଦାଗ, ଜ୍ୱର ଏବଂ କମ୍ ଥାଇରଏଡ୍ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ | ^[୬] ରୋଗ ପ୍ରତିରୋଧକ ଶକ୍ତି ହେତୁ ନିମୋନିଆ, କୋଲାଇଟିସ୍ ଏବଂ ହେପାଟାଇଟିସ ହୋଇପାରେ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲର ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ପ୍ରୋଗ୍ରାମ ହୋଇଥିବା ଡେଥ ରିସେପ୍ଟର -1 (PD-1)କୁ ଅବରୋଧ କରିଥାଏ, ଯାହାଦ୍ୱାରା ପ୍ରତିରକ୍ଷା ପ୍ରଣାଳୀ କର୍କଟ କୋଷକୁ ମାରିବାକୁ ଦେଇଥାଏ । ^[୫] ^[୬]

ଡୋଷ୍ଟାରଲିମାବ ୨୦୨୧ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୬] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ରେ ଏହାର ୫୦୦ ମିଗ୍ରାର ମୂଲ୍ୟ ୧୧.୪୦୦ ଡଲାର ଥିଲା । ^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ରାଶି ପ୍ରାୟ ୫,୯୦୦ ପାଉଣ୍ଡ ଅଟେ ।^[୮]

ଆଧାର

1 2 "Jemperli APMDS". Therapeutic Goods Administration (TGA). 2 March 2022. Archived from the original on 19 March 2022. Retrieved 5 March 2022.
↑ "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.
↑ "Summary Basis of Decision (SBD) for Jemperli". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
↑ "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Archived from the original on 22 April 2021. Retrieved 22 April 2021. This article incorporates text from this source, which is in the public domain.
1 2 3 4 5 6 7 8 "Jemperli- dostarlimab injection". DailyMed. Archived from the original on 1 March 2022. Retrieved 28 April 2021.
1 2 3 4 5 6 "Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Archived from the original on 14 May 2022. Retrieved 16 July 2021.
↑ "Jemperli Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 June 2022. Retrieved 22 July 2022.
↑ "Dostarlimab". SPS - Specialist Pharmacy Service. 16 March 2019. Archived from the original on 11 February 2022. Retrieved 22 July 2022.

[Jemperli_APMDS-1] 1 2 "Jemperli APMDS". Therapeutic Goods Administration (TGA). 2 March 2022. Archived from the original on 19 March 2022. Retrieved 5 March 2022.

[2] "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.

[3] "Summary Basis of Decision (SBD) for Jemperli". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

[FDA_PR_20210422-4] "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". U.S. Food and Drug Administration (FDA) (Press release). 22 April 2021. Archived from the original on 22 April 2021. Retrieved 22 April 2021. This article incorporates text from this source, which is in the public domain.

[Daily2022-5] 1 2 3 4 5 6 7 8 "Jemperli- dostarlimab injection". DailyMed. Archived from the original on 1 March 2022. Retrieved 28 April 2021.

[EPAR2022-6] 1 2 3 4 5 6 "Jemperli EPAR". European Medicines Agency (EMA). 24 February 2021. Archived from the original on 14 May 2022. Retrieved 16 July 2021.

[7] "Jemperli Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 June 2022. Retrieved 22 July 2022.

[8] "Dostarlimab". SPS - Specialist Pharmacy Service. 16 March 2019. Archived from the original on 11 February 2022. Retrieved 22 July 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]